In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person‐centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision‐making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried‐over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)—Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)—on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally‐enabled PCC in AIT.

中文翻译：

---

过敏原免疫治疗中的数字化、以人为本的护理 (PCC)：ARIA-EAACI 立场文件

在鼻炎和哮喘方面，已经开发了几种移动医疗应用程序，但只有少数经过验证。然而，这些应用程序在改善以人为本的护理 (PCC) 方面具有很大潜力，尤其是在过敏原免疫治疗 (AIT) 方面。他们可以通过选择适当的患者和过敏原共同决策来为 AIT 启动提供支持。它们还可以帮助（i）评估（早期）疗效，（ii）早期和晚期停止规则以及（iii）评估治疗过程停止后的（延续）疗效。过敏性鼻炎及其对哮喘的影响 (ARIA) 和欧洲过敏与临床免疫学学会 (EAACI) 联合工作组 (TF) 关于数字生物标志物的第一份报告阐述了未来的前景。 AIT 工作组现在的目标是 (i) 概述移动医疗解决方案临床应用的潜力，(ii) 表达其当前的局限性，(iii) 就临床实践和科学目的的进一步发展提出建议，以及 (iv) 提出建议这些工具可能最符合 AIT 中数字化 PCC 的目的。